Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 9, 2010
Wed, December 8, 2010 
SAN MATEO, Calif.--([ BUSINESS WIRE ])--Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today presented an overview of Deltagen's business, including its Benten Bioservices (aBentena) opportunity, at the Bio-Life-Tech 2010 conference in Baltimore, Maryland. A slide deck summarizing the presentation has been posted on the Companya™s website at [ www.deltagen.com ].
"Management's Discussion and Analysis of Financial Conditions and Results of Operations"
Deltagen's cash is expected to be sufficient to support the purchase of initial capital equipment and the build-out of Benten's Malvern, Pennsylvania facility. Deltagen is seeking funds to support its Benten operations through profitability and to position the Company for future growth. There can be no assurance that Deltagen will be successful in raising these funds or that Benten will reach profitability. This release is not an offer to sell, nor the solicitation of an offer to buy, securities.
About Deltagen
Deltagen, Inc. is a leading provider of drug discovery tools to the biopharmaceutical industry. Deltagen offers access to its extensive inventory of knockout mouse lines and related phenotypic data, which enhance the efficiency of target validation and drug discovery. In addition, Deltagen offers target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Inc. and Pfizer Inc. Benten BioServices, Inc. (aBentena), a wholly-owned subsidiary of Deltagen based in Malvern, Pennsylvania, will provide regulatory-compliant services to support the development and commercialization of biopharmaceutical products. Bentena™s services are designed to address specific requirements for critical stages in product development, including biosafety testing, raw materials testing, assay and process validation services, cell banking and characterization services, and technology platform-specific R&D support and consulting services. For more information on Deltagen, visit the Company's website at [ www.deltagen.com ].
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Deltagen's future revenues, cash flows and operating results, Benten's business plans, as well as other matters that are not historical facts or information.These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Deltagen's ability to achieve its operational objectives and revenue projections, that may cause Deltagen's actual results to be materially different from any future results expressed or implied by such forward-looking statements. There are no assurances that the Company will be able to fulfill its financial obligations, obtain sufficient additional cash to fund its Benten operations, succeed in pursuing its business plan, or achieve profitability or future growth consistent with its current projections.Information identifying such important risk factors is contained in the Company's most recent "Management's Discussion and Analysis of Financial Conditions and Results of Operations", which can be found at Deltagen's website at [ www.deltagen.com ].Deltagen undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
